Breakthrough candida Infection in a preterm infant with congenital cutaneous Candida albicans infection.
Amphotericin B is the primary antifungal agent used for candida sepsis in neonates. Breakthrough candidemia was not reported in neonates during either amphotericin B or liposomal amphotericin B (AmBisome) treatment. We describe a case of a premature infant with congenital cutaneous candida infection, who had two episodes of breakthrough infection, from Candida albicans and Candida parapsilosis, while he was treated with amphotericin B and AmBisome, respectively. We discuss the pathogenesis of breakthrough infections, and the relevance of antifungal resistance and sensitivities testing.
Adler
Amos
A
Department of Neonatology, Meir Medical Center, Kfar-Saba 95847, Israel.
Litmanovitz
Ita
I
Regev
Rivka
R
Arnon
Shmuel
S
Bauer
Sophia
S
Dolfin
Tzipora
T
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000097:blood* / Q000382:microbiology; D002177:Candidiasis / Q000097:blood*; D002179:Candidiasis, Cutaneous / Q000151:congenital* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D008297:Male; D008826:Microbial Sensitivity Tests; D011247:Pregnancy
D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B